Dermata Therapeutics (NASDAQ:DRMA) Trading Down 0.8% – Should You Sell?

Shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA) traded down 0.8% on Tuesday . The stock traded as low as $1.18 and last traded at $1.19. 41,020 shares changed hands during trading, a decline of 23% from the average session volume of 53,535 shares. The stock had previously closed at $1.20.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Weiss Ratings cut Dermata Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday, June 4th. Wall Street Zen raised Dermata Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Dermata Therapeutics has a consensus rating of “Hold” and a consensus target price of $10.00.

Dermata Therapeutics Price Performance

The company has a market capitalization of $4.78 million, a price-to-earnings ratio of -0.22 and a beta of 0.69. The firm has a 50-day moving average price of $1.26 and a two-hundred day moving average price of $1.68.

Dermata Therapeutics (NASDAQ:DRMA) last released its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.05.

Institutional Trading of Dermata Therapeutics

An institutional investor recently bought a new position in Dermata Therapeutics stock. Clear Street Group Inc. bought a new position in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned approximately 0.60% of Dermata Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 8.67% of the company’s stock.

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.